Artificial intelligence to guide precision anticancer therapy with multitargeted kinase inhibitors
© 2022. The Author(s)..
BACKGROUND: Vast amounts of rapidly accumulating biological data related to cancer and a remarkable progress in the field of artificial intelligence (AI) have paved the way for precision oncology. Our recent contribution to this area of research is CancerOmicsNet, an AI-based system to predict the therapeutic effects of multitargeted kinase inhibitors across various cancers. This approach was previously demonstrated to outperform other deep learning methods, graph kernel models, molecular docking, and drug binding pocket matching.
METHODS: CancerOmicsNet integrates multiple heterogeneous data by utilizing a deep graph learning model with sophisticated attention propagation mechanisms to extract highly predictive features from cancer-specific networks. The AI-based system was devised to provide more accurate and robust predictions than data-driven therapeutic discovery using gene signature reversion.
RESULTS: Selected CancerOmicsNet predictions obtained for "unseen" data are positively validated against the biomedical literature and by live-cell time course inhibition assays performed against breast, pancreatic, and prostate cancer cell lines. Encouragingly, six molecules exhibited dose-dependent antiproliferative activities, with pan-CDK inhibitor JNJ-7706621 and Src inhibitor PP1 being the most potent against the pancreatic cancer cell line Panc 04.03.
CONCLUSIONS: CancerOmicsNet is a promising AI-based platform to help guide the development of new approaches in precision oncology involving a variety of tumor types and therapeutics.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
BMC cancer - 22(2022), 1 vom: 24. Nov., Seite 1211 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Singha, Manali [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 29.11.2022 Date Revised 13.12.2022 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12885-022-10293-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM349474745 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM349474745 | ||
| 003 | DE-627 | ||
| 005 | 20231226042716.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12885-022-10293-0 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1164.xml |
| 035 | |a (DE-627)NLM349474745 | ||
| 035 | |a (NLM)36434556 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Singha, Manali |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Artificial intelligence to guide precision anticancer therapy with multitargeted kinase inhibitors |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.11.2022 | ||
| 500 | |a Date Revised 13.12.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s). | ||
| 520 | |a BACKGROUND: Vast amounts of rapidly accumulating biological data related to cancer and a remarkable progress in the field of artificial intelligence (AI) have paved the way for precision oncology. Our recent contribution to this area of research is CancerOmicsNet, an AI-based system to predict the therapeutic effects of multitargeted kinase inhibitors across various cancers. This approach was previously demonstrated to outperform other deep learning methods, graph kernel models, molecular docking, and drug binding pocket matching | ||
| 520 | |a METHODS: CancerOmicsNet integrates multiple heterogeneous data by utilizing a deep graph learning model with sophisticated attention propagation mechanisms to extract highly predictive features from cancer-specific networks. The AI-based system was devised to provide more accurate and robust predictions than data-driven therapeutic discovery using gene signature reversion | ||
| 520 | |a RESULTS: Selected CancerOmicsNet predictions obtained for "unseen" data are positively validated against the biomedical literature and by live-cell time course inhibition assays performed against breast, pancreatic, and prostate cancer cell lines. Encouragingly, six molecules exhibited dose-dependent antiproliferative activities, with pan-CDK inhibitor JNJ-7706621 and Src inhibitor PP1 being the most potent against the pancreatic cancer cell line Panc 04.03 | ||
| 520 | |a CONCLUSIONS: CancerOmicsNet is a promising AI-based platform to help guide the development of new approaches in precision oncology involving a variety of tumor types and therapeutics | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Artificial intelligence | |
| 650 | 4 | |a Cancer growth rate | |
| 650 | 4 | |a Cancer-specific networks | |
| 650 | 4 | |a Differential gene expression | |
| 650 | 4 | |a Gene signature | |
| 650 | 4 | |a Gene-disease association | |
| 650 | 4 | |a Graph neural network | |
| 650 | 4 | |a Kinase inhibitors | |
| 650 | 4 | |a Live-cell time course assay | |
| 650 | 4 | |a Network biology | |
| 650 | 4 | |a Precision oncology | |
| 700 | 1 | |a Pu, Limeng |e verfasserin |4 aut | |
| 700 | 1 | |a Stanfield, Brent A |e verfasserin |4 aut | |
| 700 | 1 | |a Uche, Ifeanyi K |e verfasserin |4 aut | |
| 700 | 1 | |a Rider, Paul J F |e verfasserin |4 aut | |
| 700 | 1 | |a Kousoulas, Konstantin G |e verfasserin |4 aut | |
| 700 | 1 | |a Ramanujam, J |e verfasserin |4 aut | |
| 700 | 1 | |a Brylinski, Michal |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC cancer |d 2001 |g 22(2022), 1 vom: 24. Nov., Seite 1211 |w (DE-627)NLM111431948 |x 1471-2407 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2022 |g number:1 |g day:24 |g month:11 |g pages:1211 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12885-022-10293-0 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2022 |e 1 |b 24 |c 11 |h 1211 | ||